Recent Security Class Actions

According to the Complaint, Anaptysbio, Inc.is a clinical stage biotechnology company focused on the discovery and development of drugs for the treatment of inflammation and immuno-oncology conditions with unmet medical needs. During the Class Period, the Company’s lead drug asset was etokimab (formerly ANB020), a drug intended for the treatment of various inflammatory diseases.